Accendra Health revised its full-year 2026 revenue guidance to between $2.45 billion and $2.55 billion and adjusted EBITDA to between $300 million and $320 million, while CEO Edward Pesicka announced his intention to retire by the end of 2026. The company cited three primary factors for the shortfall: revenue growth below expectations, timing of planned cost reductions, and a slower-than-expected recovery of its collection rate, which had a negative impact of nearly $20 million in the first half. Second-quarter adjusted EBITDA was just over $60 million, and free cash flow for the full year is now expected to be breakeven to slightly positive. Management noted that more than $125 million of annualized costs have been eliminated following the separation from Owens & Minor and the transition away from a large commercial payor, and that a stronger fourth quarter is expected to provide momentum into 2027.
Accendra Health IncCompany cuts 2026 revenue and EBITDA guidance, and CEO announces retirement, signaling weaker financial performance.
